CDK9 inhibition blocks the initiation of PINK1-PRKN-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic effects involving mitochondrial dysfunction in hepatocellular carcinoma

References

• Esteban-Martinez L, Sierra-Filardi E, McGreal RS, et al. Programmed mitophagy is essential for the glycolytic switch during cell differentiation. EMBO J. 2017;36:1688–1706.
   PubMed Web of Science ®Google Scholar
• Prieto-Dominguez N, Ordonez R, Fernandez A, et al. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. J Pineal Res. 2016;61:396–407.
   PubMed Web of Science ®Google Scholar
• Chang JY, Yi HS, Kim HW, et al. Dysregulation of mitophagy in carcinogenesis and tumor progression. Biochim Biophys Acta Bioenerg. 2017;1858:633–640.
   PubMed Web of Science ®Google Scholar
• Tabish TA, Zhang S, Winyard PG, et al. Developing the next generation of graphene-based platforms for cancer therapeutics: the potential role of reactive oxygen species. Redox Biol. 2018;15:34–40.
   PubMed Web of Science ®Google Scholar
• Zhou H, Wang J, Zhu P, et al. NR4A1 aggravates the cardiac microvascular ischemia reperfusion injury through suppressing FUNDC1-mediated mitophagy and promoting Mff-required mitochondrial fission by CK2alpha. Basic Res Cardiol. 2018;113:23.
   PubMed Web of Science ®Google Scholar
• Zhou H, Zhu P, Wang J, et al. Pathogenesis of cardiac ischemia reperfusion injury is associated with CK2alpha-disturbed mitochondrial homeostasis via suppression of FUNDC1-related mitophagy. Cell Death Differ. 2018;25:1080–1093.
   PubMed Web of Science ®Google Scholar
• Chourasia AH, Macleod KF. Tumor suppressor functions of BNIP3 and mitophagy. Autophagy. 2015;11:1937–1938.
   PubMed Web of Science ®Google Scholar
• Chen LY, Yang B, Zhou L, et al. Promotion of mitochondrial energy metabolism during hepatocyte apoptosis in a rat model of acute liver failure. Mol Med Rep. 2015;12:5035–5041.
   PubMedGoogle Scholar
• Braggio D, Koller D, Jin F, et al. Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors. Cancer. 2019;125:2693–2703.
   PubMedGoogle Scholar
• Fan S, Price T, Huang W, et al. PINK1-dependent mitophagy regulates the migration and homing of multiple myeloma cells via the MOB1B-mediated Hippo-YAP/TAZ pathway. Adv Sci (Weinh). 2020;7:1900860.
   PubMedGoogle Scholar
• Wu H, Wang T, Liu Y, et al. Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis. J Exp Clin Cancer Res. 2020;39:274.
   PubMed Web of Science ®Google Scholar
• Yan C, Luo L, Guo CY, et al. Doxorubicin-induced mitophagy contributes to drug resistance in cancer stem cells from HCT8 human colorectal cancer cells. Cancer Lett. 2017;388:34–42.
   PubMed Web of Science ®Google Scholar
• Chourasia AH, Boland ML, Macleod KF, et al. Mitophagy and cancer. Cancer Metab. 2015;3:4.
   PubMed Web of Science ®Google Scholar
• Jin SM, Lazarou M, Wang C, et al. Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. J Cell Biol. 2010;191:933–942.
   PubMed Web of Science ®Google Scholar
• Zhang C, Liu Z, Bunker E, et al. Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response. J Biol Chem. 2017;292:15105–15120.
   PubMed Web of Science ®Google Scholar
• Hoshino A, Mita Y, Okawa Y, et al. Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart. Nat Commun. 2013;4:2308.
   PubMed Web of Science ®Google Scholar
• Dashzeveg N, Yoshida K. Cell death decision by p53 via control of the mitochondrial membrane. Cancer Lett. 2015;367:108–112.
   PubMedGoogle Scholar
• Liu K, Lee J, Kim JY, et al. Mitophagy controls the activities of tumor suppressor p53 to regulate hepatic cancer stem cells. Mol Cell. 2017;68:281–92 e5.
   PubMed Web of Science ®Google Scholar
• Morales F, Giordano A. Overview of CDK9 as a target in cancer research. Cell Cycle. 2016;15:519–527.
   PubMed Web of Science ®Google Scholar
• Yao JY, Xu S, Sun YN, et al. Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling. Acta Pharmacol Sin. 2021. DOI: https://doi.org/10.1038/s41401-021-00708-2
   Google Scholar
• Price NL, Gomes AP, Ling AJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;15:675–690.
   PubMed Web of Science ®Google Scholar
• Ou X, Lee MR, Huang X, et al. SIRT1 positively regulates autophagy and mitochondria function in embryonic stem cells under oxidative stress. Stem Cells. 2014;32:1183–1194.
   PubMed Web of Science ®Google Scholar
• Motta MC, Divecha N, Lemieux M, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell. 2004;116:551–563.
   PubMed Web of Science ®Google Scholar
• Eijkelenboom A, Burgering BM. FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol. 2013;14:83–97.
   PubMed Web of Science ®Google Scholar
• Lu P, Kamboj A, Gibson SB, et al. Poly(ADP-ribose) polymerase-1 causes mitochondrial damage and neuron death mediated by Bnip3. J Neurosci. 2014;34:15975–15987.
   PubMedGoogle Scholar
• Ma X, McKeen T, Zhang J, et al. Role and mechanisms of mitophagy in liver diseases. Cells. 2020;9:837.
   PubMed Web of Science ®Google Scholar
• Georgakopoulos ND, Wells G, Campanella M, et al. The pharmacological regulation of cellular mitophagy. Nat Chem Biol. 2017;13:136–146.
   PubMed Web of Science ®Google Scholar
• Katayama H, Kogure T, Mizushima N, et al. A sensitive and quantitative technique for detecting autophagic events based on lysosomal delivery. Chem Biol. 2011;18:1042–1052.
   PubMedGoogle Scholar
• Sun N, Malide D, Liu J, et al. A fluorescence-based imaging method to measure in vitro and in vivo mitophagy using mt-Keima. Nat Protoc. 2017;12:1576–1587.
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abdelmohsen K, Abe A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12:1–222.
   PubMed Web of Science ®Google Scholar
• Soutar MPM, Kempthorne L, Annuario E, et al. FBS/BSA media concentration determines CCCP’s ability to depolarize mitochondria and activate PINK1-PRKN mitophagy. Autophagy. 2019;15:2002–2011.
   PubMed Web of Science ®Google Scholar
• Niu K, Fang H, Chen Z, et al. USP33 deubiquitinates PRKN/parkin and antagonizes its role in mitophagy. Autophagy. 2020 Apr;16:724–734.
   PubMed Web of Science ®Google Scholar
• Zhang H, Pandey S, Travers M, et al. Targeting CDK9 reactivates epigenetically silenced genes in cancer. Cell. 2018;175:1244–58 e26.
   PubMed Web of Science ®Google Scholar
• Allen GF, Toth R, James J, et al. Loss of iron triggers PINK1/Parkin-independent mitophagy. EMBO Rep. 2013;14:1127–1135.
   PubMed Web of Science ®Google Scholar
• Zhang T, Xue L, Li L, et al. BNIP3 protein suppresses PINK1 kinase proteolytic cleavage to promote mitophagy. J Biol Chem. 2016;291:21616–21629.
   PubMed Web of Science ®Google Scholar
• Wei L, Dai Y, Zhou Y, et al. Oroxylin A activates PKM1/HNF4 alpha to induce hepatoma differentiation and block cancer progression. Cell Death Dis. 2017;8:e2944.
   PubMedGoogle Scholar
• Teicher BA. Tumor models for efficacy determination. Mol Cancer Ther. 2006;5:2435–2443.
   PubMed Web of Science ®Google Scholar
• Yan, C, Luo, L, Guo, CY, et al. Doxorubicin-induced mitophagy contributes to drug resistance in cancer stem cells from HCT8 human colorectal cancer cells. Cancer Lett. 2017;388:34–42.
   PubMed Web of Science ®Google Scholar
• Yao N, Wang C, Hu N, et al. Inhibition of PINK1/Parkin-dependent mitophagy sensitizes multidrug-resistant cancer cells to B5G1, a new betulinic acid analog. Cell Death Dis. 2019;10:232.
   PubMedGoogle Scholar
• Alexa-Stratulat T, Pesic M, Gasparovic AC, et al. What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg. Drug Resist Updat. 2019;46:100643.
   PubMedGoogle Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249.
   PubMed Web of Science ®Google Scholar
• Sheng J, Shen L, Sun L, et al. Inhibition of PI3K/mTOR increased the sensitivity of hepatocellular carcinoma cells to cisplatin via interference with mitochondrial-lysosomal crosstalk. Cell Prolif. 2019;52:e12609.
   PubMed Web of Science ®Google Scholar
• Song J, Zhao W, Lu C, et al. LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib-mediated death via inhibiting the AMPK-Mfn2 signaling pathway. Cancer Cell Int. 2019;19:60.
   PubMedGoogle Scholar
• Zheng L, Li C, Huang X, et al. Thermosensitive hydrogels for sustained-release of sorafenib and selenium nanoparticles for localized synergistic chemoradiotherapy. Biomaterials. 2019;216:119220.
   PubMed Web of Science ®Google Scholar
• Amaravadi RK, Kimmelman AC, Debnath J, et al. Targeting autophagy in cancer: recent advances and future directions. Cancer Discov. 2019;9:1167–1181.
   PubMed Web of Science ®Google Scholar
• Yan C, Li TS. Dual role of mitophagy in cancer drug resistance. Anticancer Res. 2018;38:617–621.
   PubMedGoogle Scholar
• Bernardini JP, Lazarou M, Dewson G, et al. Parkin and mitophagy in cancer. Oncogene. 2017;36:1315–1327.
   PubMed Web of Science ®Google Scholar
• Kume S, Uzu T, Horiike K, et al. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest. 2010;120:1043–1055.
   PubMed Web of Science ®Google Scholar
• Naik PP, Birbrair A, Bhutia SK, et al. Mitophagy-driven metabolic switch reprograms stem cell fate. Cell Mol Life Sci. 2019;76:27–43.
   PubMed Web of Science ®Google Scholar
• Maycotte P, Aryal S, Cummings CT, et al. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy. 2012;8:200–212.
   PubMed Web of Science ®Google Scholar
• Maes H, Kuchnio A, Peric A, et al. Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell. 2014;26:190–206.
   PubMed Web of Science ®Google Scholar
• Kai J, Yang X, Wang Z, et al. Oroxylin a promotes PGC-1alpha/Mfn2 signaling to attenuate hepatocyte pyroptosis via blocking mitochondrial ROS in alcoholic liver disease. Free Radic Biol Med. 2020;153:89–102.
   PubMed Web of Science ®Google Scholar
• Wei L, Zhou Y, Qiao C, et al. Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1alpha destabilization. Cell Death Dis. 2015;6:e1714.
   PubMed Web of Science ®Google Scholar
• Ni T, He Z, Dai Y, et al. Oroxylin A suppresses the development and growth of colorectal cancer through reprogram of HIF1alpha-modulated fatty acid metabolism. Cell Death Dis. 2017;8:e2865.
   PubMedGoogle Scholar
• Dai Q, Yin Q, Wei L, et al. Oroxylin A regulates glucose metabolism in response to hypoxic stress with the involvement of Hypoxia-inducible factor-1 in human hepatoma HepG2 cells. Mol Carcinog. 2016;55:1275–1289.
   PubMedGoogle Scholar